Gene regulatory variation in the developing human brain and its role in neuropsychiatric disorders

Lead Research Organisation: King's College London
Department Name: Neuroscience

Abstract

Large genetic studies, involving many thousands of individuals, have identified several regions of the genome where DNA variation increases risk for major psychiatric disorders such as schizophrenia. However, the biological mechanisms by which these genetic variants confer risk to these disorders are currently unknown. It is believed that many of these risk variants operate by changing the amount, or 'expression', of nearby genes in the brain, and, further, that these effects start very early in brain development. To test this hypothesis, we will examine DNA variants across the entire genome and relate these to highly sophisticated measures of gene expression in the developing human brain. These studies will greatly advance our understanding of major psychiatric disorders, which will serve as a basis for improved treatments for these conditions.

Technical Summary

Large-scale genetic studies have successfully identified genetic loci conferring susceptibility to major neuropsychiatric disorders such as schizophrenia. As the most strongly associated variants are typically in non-coding regions of the genome, it is likely that risk is commonly mediated through effects on gene expression. However, the genes that are affected, the way in which they are functionally altered (e.g. up- or down- regulation) and where and when the effects are exerted are currently unclear. Given that several neuropsychiatric disorders are thought to have a neurodevelopmental component, we will explore effects of identified risk variants for these disorders on the expression of proximally located genes in the developing human brain. One hundred foetal brain samples will be genome-wide genotyped for >1 million single nucleotide polymorphisms and the corresponding RNA deep sequenced to provide whole transcriptome measures of gene expression. We will use these data to identify those genes that are differentially expressed in the developing brain in association with neuropsychiatric risk variants and to determine the way in which they are functionally altered. We will also perform a genome-wide assessment of genes that are differentially regulated in the developing human brain as a result of common genetic variation and seek to identify downstream changes in gene expression associated with altered regulation of neuropsychiatric susceptibility genes. These studies will greatly improve our understanding of the aetiology and underlying biology of neuropsychiatric conditions as well as of gene regulation in the developing human brain.

Planned Impact

Although neuropsychiatric disorders are common and associated with considerable individual and societal burden, we know incredibly little about the underlying neurobiology of these conditions. Elucidating the molecular mechanisms by which identified genetic risk variants operate will be an essential first step in advancing our biological understanding of these disorders, with the ultimate goal of developing improved treatments and possibly even prevention strategies.

In the short term, the primary beneficiaries of our research will be other researchers in academia and industry. Our analyses of the data, with the primary aim of identifying genetic risk mechanisms for neuropsychiatric disorders operating during foetal brain development, will particularly benefit the research of others seeking to understand the biological basis of these disorders. For example, it will foster more valid animal models for these conditions, with which improved therapies can be developed and tested. However, given its genome-wide nature, the raw and processed data will also be useful to scientists more generally; for example, by indicating novel RNA transcripts expressed during human brain development or in allowing researchers to test effects of genetic variants implicated in other brain phenotypes on gene expression in the developing brain.

We will ensure maximum impact of this research through open access publishing in leading science journals, review articles, conference presentations and extensive data sharing.

Publications

10 25 50
publication icon
Duarte RRR (2016) Genome-wide significant schizophrenia risk variation on chromosome 10q24 is associated with altered cis-regulation of BORCS7, AS3MT, and NT5C2 in the human brain. in American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics

 
Title EGAD00001004363 
Description FastQ files with paired-end RNAseq data for human fetal brain homogenate from 120 samples (12-19 post-conception weeks). Available through the European Genome-phenome archive, 
Type Of Material Database/Collection of data 
Year Produced 2018 
Provided To Others? Yes  
Impact This dataset is controlled access as it contains human genotype information. However, so far it has been accessed (after data access committee approval) by ~30 academic researchers around the world. 
URL https://www.ebi.ac.uk/ega/studies/EGAS00001003214
 
Title Human fetal brain expression SNP-weights for use in TWAS 
Description Single nucleotide polymorphism (SNP)-weights for Ensembl gene and transcript-level expression were derived from genotyping and RNA sequencing data from 120 human fetal brains aged 12 - 19 post-conception weeks. Prior to deriving SNP-weights, gene- and transcript-level expression data were normalized and adjusted for sex, age, RIN, sequencing batch, 3 genotype principal components and 10 PEER factors. For a full description of the sample and data generation, please see: https://genomebiology.biomedcentral.com/articles/10.1186/s13059-018-1567-1Expression weights for use in transcriptome-wide association studies (TWAS) were derived using FUSION software (http://gusevlab.org/projects/fusion/#computing-your-own-functional-weights). SNP-weights were only generated for genes and transcripts with significant evidence of cis-heritable expression at the default P-value (P < 0.01) in FUSION (1351 Ensembl genes and 3985 Ensembl transcripts). Note that the number of genes that will be testable by TWAS may differ as this will depend on the number of overlapping SNPs between the weights files and the GWAS summary statistics.Expression weights were derived using only SNPs available in the FUSION LD reference (HapMap3 SNPs), in line with the FUSION protocol. Expression weights provided here are in the same format as weights downloaded from the FUSION website.Use of these expression weights to perform TWAS of attention deficit hyperactivity disorder (ADHD), autism spectrum disorder, bipolar disorder, major depressive disorder and schizophrenia are described in Hall et al. 'Cis-effects on gene expression in the human prenatal brain associated with genetic risk for neuropsychiatric disorders' Molecular Psychiatry (in press).Files:- Ensembl gene level weights: op-fusion-fetal_brain-full_sample-gene_level.tar.gz - Ensembl transcript level weights: op-fusion-fetal_brain-full_sample-transcript_level.tar.gz 
Type Of Material Database/Collection of data 
Year Produced 2020 
Provided To Others? Yes  
Impact This dataset will allow other researchers to test associations between brain phenotypes and genetically-predicted gene expression in human fetal brain. 
URL https://figshare.com/articles/Human_fetal_brain_expression_SNP-weights_for_use_in_TWAS/11637036/1
 
Title Summary statistics for expression quantitative trait loci in the developing human brain and their enrichment in neuropsychiatric disorders 
Description This dataset contains summary statistics for eQTL (Expression Quantitative Trait Loci) analyses using 120 human fetal brains from the second trimester of gestation (12 to 19 post-conception weeks). Expression matrices, covariates, and summary statistics are provided for all tested eQTL and for top eQTL for all genes and transcripts. 
Type Of Material Database/Collection of data 
Year Produced 2018 
Provided To Others? Yes  
Impact As of 12th Feb 2019, the data have been downloaded 135 times in the 2.5 months that they have been available. 
URL https://doi.org/10.6084/m9.figshare.6881825
 
Description Collaboration with Complex disease epigenetics group at the University of Exeter Medical School 
Organisation University of Exeter
Department Medical School
Country United Kingdom 
Sector Academic/University 
PI Contribution We have contributed samples, genotype information and RNA sequencing from human foetal brain. I have also led on writing or co-wrote several of the papers on which we are joint authors.
Collaborator Contribution Professor Jon Mill and colleagues at the University of Exeter have contributed statistical analyses, DNA methylation data and led or co-wrote several of the papers on which we are joint authors. Professor Mill is also a co-supervisor on the GW4 MRC DTP 'Sites of active gene regulation in the developing human brain and their role in neuropsychiatric disorders'.
Impact O'Brien HE, Hannon E, Hill MJ, Toste CC, Robertson MJ, Morgan JE, McLaughlin G, Lewis CM, Schalkwyk LC, Hall LS, Pardiñas AF, Owen MJ, O'Donovan MC, Mill J, Bray NJ (2018) Expression quantitative trait loci in the developing human brain and their enrichment in neuropsychiatric disorders. Genome Biol.19: 194 Spiers H, Hannon E, Schalkwyk LC, Bray NJ, Mill J (2017) 5-hydroxymethylcytosine is highly dynamic across human fetal brain development. BMC Genomics 18: 738. Hannon E, Spiers H, Viana J, Pidsley R, Burrage J, Murphy TM, Troakes C, Turecki G, O'Donovan MC, Schalkwyk LC, Bray NJ, Mill J (2016) Methylation QTLs in the developing brain and their enrichment in schizophrenia risk loci. Nature Neuroscience 19: 48-54 Spiers H, Hannon E, Schalkwyk L, Smith R, Wong C, O'Donovan MC, Bray NJ, Mill J. (2015) Methylomic trajectories across human fetal brain development. Genome Research 25: 338-52. Pidsley R, Viana J, Hannon E, Spiers H, Troakes C, Al-Saraj S, Mechawar N, Turecki G, Schalkwyk L, Bray NJ, Mill J (2014) Methylomic profiling of human brain tissue supports a neurodevelopmental origin for schizophrenia. Genome Biology 15: 483
Start Year 2013